A simple blood draw could spot colorectal cancer early
NCT ID NCT07035691
First seen Aug 12, 2026 · Last updated Aug 13, 2026 · Updated 1 time
Summary
This study is testing whether a blood test can accurately identify colorectal cancer or polyps in adults referred for suspected lower GI cancer. Participants provide a blood sample during their routine diagnostic visit, and their results are compared to their final diagnosis. The study also explores patient preferences for blood-based tests versus more invasive procedures like colonoscopy.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- A blood test measuring progastrin (hPG80) and transposable elements (TEs)
- What this could lead to
- If accurate, this blood test could offer a less invasive way to detect colorectal cancer and polyps, potentially reducing the need for colonoscopies.
- What could go wrong
- This is an observational study, so it won't prove the test works in practice. The biomarkers may not be accurate enough, and results may not apply to all patients.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for COLORECTAL ADENOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Barts Health NHS Trust
RECRUITINGLondon, England, E1 2AT, United Kingdom
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a plasma beam stop colon polyps from coming back?
- A stitch in time: could a device make abdominal closure safer?
- Can we predict chemo brain before it happens?
- Your gut bacteria might reveal hidden cancer risk
- Can a smart digital program restore sleep for cancer survivors?
- Can a new infusion drug shrink Hard-to-Treat tumors?